A longterm, double blind intervention trial was undertaken in patients with sporadic adenoma treated by polypectomy to investigate the putative role of calcium as a protective factor in colon carcinogenesis. The aim of the study was to assess the effect ofa daily dietary supplementation of 2 g calcium over nine months on cell proliferation measured as proliferation index in colonic mucosa. A total of 48 patients were entered into the study of which 30 were fuily compliant. After intervention proliferation index % (mean (SEM) in colonic epithelium was decreased in both the calcium (13.5 (1.5) to 114 (1.2)) and the placebo group (13.7 (0.9) to 10*8 (1 1)). The difference in the change between the two groups was not significant (p=0. 7). Changes in proliferation index % of crypt compartments were also not significantly different between the two groups. A significantly positive correlation between soluble calcium in faeces and the total proliferation index % in colonic epithelium at baseline and after intervention (r=0.54, p<001, r=0'50, p<0 01 respectively) suggests that an increase of free luminal calcium alone is insufficient for inhibition of cellular proliferation. (Gut 1996; 38: 396-402 show a reduction in crypt cell production rate in the rectal epithelium.18 Furthermore, except for one short-term study relating to cell proliferation in the sigmoid colon,'4 the effect of calcium supplementation has been confined to the rectum.
Cell proliferation is increased in colonic epithelium of patients at high risk for colorectal cancer, such as in patients with sporadic colorectal adenomasl-3 or carcinomas,4 5 show a reduction in crypt cell production rate in the rectal epithelium.18 Furthermore, except for one short-term study relating to cell proliferation in the sigmoid colon,'4 the effect of calcium supplementation has been confined to the rectum.
The aim of this study was to investigate if intervention with 2 g calcium/day over a period of nine months would decrease cell proliferation in the sigmoid mucosa of patients treated by polypectomy using a randomised, double blind, placebo controlled protocol. Correlation of proliferative activity at baseline with known risk factors such as age, adenoma size, and grade of dysplasia was also investigated.
Methods

Study design
Participants were recruited over a period of nine months from patients attending endoscopic units in eight hospitals in Heidelberg and surrounding areas with one physician being responsible for recruiting patients and biopsying in each hospital. Patients with newly diagnosed colorectal adenomas who were 30-75 years of age were eligible for the study. Additional inclusion criteria were a histologically confirmed adenomatous polyp larger than 4 mm, informed consent about participation in the study, and biopsy for determination of cell proliferation. Biopsy specimens were obtained at the initial colonoscopy from macroscopically normal mucosa at the rectosigmoidal junction (about 20 cm from the anal verge) but at least 5 cm from any neoplastic lesion, using standard forceps. Number, size, and localisation of polyps and whether or not they were removed, were recorded.
Exclusion criteria included conditions predisposing to colorectal cancer other than sporadic adenomas, contraindications to calcium supplementation or to biopsy sample excision, conditions indicating severe restriction of general health, or drug use that may interfere with the study. In particular, exclusion criteria were as follows: FAP; inflammatory bowel disease; chronic alcohol abuse; intestinal malabsorption syndromes; cancer other than nonmelanoma skin cancer; renal insufficiency; gastrectomy, ileostomy, colectomy; vegetarian diet; consumption of more than 1 litre milk per day or more than 600 g dairy products per day (milk-alkali-syndrome); renal stones, haematuria; sarcoidosis; hyperparathyroidism; hypercalcaemia; abnormal serum calcium or creatinine concentrations at the time of initial Effect oflongterm placebo controlled calcium supplementation on sigtoidal cell proliferation in patients with sporadic adenomatous polyps colonoscopy; cholestyramine treatment; calcium or vitamin D supplementation; anticoagulant treatment, problems in understanding the nature of the study; and place of residence more than 100 km from the study centre.
Eligible patients were followed up immediately after the initial polypectomy and subsequently every three months at their private residences. Before entering the actual treatment phase, participants were asked to collect 48 hour stool and 24 hour urine samples. The usual dietary intake was assessed with a self administered food frequency questionnaire. Study participants were asked to continue their normal Western style diet. Before randomisation, a run in phase of three months was applied in which all participants received placebo. Less Calcium analysis To 100 mg of freeze dried faeces 2 ml of concentrated HNO3 was added in a tightly sealed universal bottle. The bottles were placed in a heating block at 120°C for one hour. On cooling 10 ml 1 M HCI was added prior to analysis of total calcium by atomic absorption spectrophotometry (AAS). Soluble calcium was measured by adding 10 ml of distilled water to 100 mg of freeze dried faeces and incubating overnight at room temperature. Supernatants were again analysed by AAS. During supplementation the 24 hour recall method was used. At each follow up visit participants were asked about their food intake on the previous day. For each single food item consumed, the amount was estimated by use of household measures or portion size photos. A cross check at the end of each 24 hour recall was applied to search for previously omitted items. The detailed responses were coded according to the Federal Food Code and subsequently converted into nutrient intake.
Determination ofproliferation index For the first five patients who entered the study, cell proliferation was measured by the BrdU method. To facilitate recruitment of patients from external hospitals, however, a proliferation marker based on an endogenous cell cycle related antigen was required to circumvent immediate incubation of viable tissue. Therefore, PCNA (clone PC 10) immunohistochemistry was applied for the subsequent study participants. In any one patient, the same method was used before and after intervention. After clinical examination and, as for BrdU incubation of biopsy samples, the specimens were fixed in absolute methanol, transported to the laboratory, and processed within 24 hours. Both BrdU and PCNA protocols have been described and compared elsewhere. 20 All sections were examined by one observer who had no knowledge of the clinical features, the histological diagnosis or the random allocation to treatment groups. In a previously conducted analysis ofvariance20 the number of crypts and number ofbiopsy samples that must be evaluated to classify a subject within a certain interval was estimated. According to these findings, five crypts of each biopsy sample were evaluated whenever three samples were used for the evaluation, eight crypts of each of two biopsy samples, and 30 crypts when only one biopsy sample was available to characterise a subject at each point in time.
A crypt was analysed if its entire length was visible in the longitudinal section and the base contacted the muscularis mucosae. In each crypt column (which is the single column of epithelial cells lining one side of a sectioned crypt meeting the criteria) the total number of cells and the number of labelled cells and their position in the crypt column relative to the base of the crypt were noted. Subjects were regarded as compliant and included in the final evaluation of the effect of calcium intervention if the pill count yielded an 80% adherence to the treatment and the increase in faecal calcium excretion was greater than 1500 mg.
Mean PI% of colonic epithelial cell proliferation was determined for each group at each time point. The treatment effect was estimated and tested with Wilcoxon's rank sum test on the difference between the mean changes of PI% in each group after intervention compared with baseline. Average scores were used for ties. Results were considered statistically significant at t=0 05. Multiple regression analysis was used to adjust for confounding variables. The PI% as a function of cell position relative to crypt column base was examined separately for each group at each time point.
Results
Of 48 patients who were entered into the calcium intervention study, four were not compliant during run in phase, one died, six were not compliant during the main intervention phase and four either refused or were not able to undergo their final examination -that is, biopsy samples could not be obtained. Each of the remaining 33 participants showed a compliance greater than 80% at each pill count evaluation. In three of these participants, however, calcium excretion in faeces indicated low compliance. They were therefore excluded from the final analysis. The final statistical analysis is based on 30 participants (15 in each group) who completed the study in a full compliant manner (>96% compliance). Table I gives characteristics of the study group with respect to age, sex, and usual dietary intake. The average age of the final study group was 62 (range 46-75), 14 women and 16 men. Mean age of both groups was similar, but distribution of sex was unbalanced (Table I) 15 patients completed the study according to protocol in each group rather than the intended 21. Secondly, standard deviation of the major end point 'change in PI% after intervention as compared to baseline' was larger than anticipated. The minimum detectable difference of PI% between both groups in this study with n= 15 in each group and SD=4.75 was 4.8. Given an expected no effect in the placebo group, a decrease of PI% in the calcium group to approximately 7% of that found in healthy controls20 could have been detected as statistically significant compared with the placebo group.
After nine months of intervention a decrease of total PI% in sigmoidal mucosa was evident in both calcium (from 13-5 before to 11.4 after intervention) and placebo group (from 13.7 to 10.7) ( Table II) . The difference between the two groups regarding the change of PI% after intervention compared with baseline, was not statistically significant (p=07). The observed decrease in the calcium group could therefore not be ascribed to calcium intervention. Age, sex, and adenoma size did not influence this result when included as covariables in a regression analysis. The method of measuring cell proliferation had no influence on the change in PI% after intervention -that is, did not interfere with the main result. Five of 15 patients in the calcium group but only three of 15 in the placebo group experienced an increase in P1% (Fig 1) . There was a tendency in the calcium group for initially high values to decrease and initially low values to increase.
Proliferative activity in crypt compartments was highest in compartment 2 in both groups of patients at both time points (Table II) . PI% decreased in both groups during intervention in compartments 2, 3, and 4, whereas for the basal compartment 1, a decrease was only evident in the placebo group (Table II) (Fig 2) . Before intervention, a steep rise in proportion of labelled cells occurred to a maximum at the 20th percentile in the calcium group and the 18th percentile in the placebo group. After intervention the peak PI reverted to the 18th percentile of crypt height in the calcium group, whereas in the placebo group the maximum PI% could be found at the 20th percentile. In both groups there was a decrease of proliferative activity after intervention compared with baseline almost along the whole length of the crypt, except for the uppermost 20% and the basal 10% of the crypt. However, these differences were not significant at any cell position.
An intention to treat analysis of all randomised subjects was not possible, because five non-compliant and four compliant subjects refused to or were not able to undergo final examination -that is, biopsy samples could not be obtained. Because the study was conducted in symptom free subjects, it is very unlikely that compliance rate is related to the outcome measure. Four subjects with less than ideal compliance (<80%) did have a final examination and biopsy. Including their data in the analysis did not materially effect the results.
Daily calcium excretion in faeces increased significantly both as total calcium and soluble calcium in the calcium group compared with the corresponding change in the placebo group (Table III) . The increase in faecal calcium output of 1807 mg in the calcium group corresponds closely to 2000 mg calcium by which the diet was supplemented.
Calcium excretion in urine before intervention was in both groups on average 85 mg/day (Table III) , which is well below the obligatory amount of renal calcium loss under conditions of calcium balance (114-116 mg/day),22 showing a negative calcium balance in these patients. After intervention with 2 g calcium per day for six months renal calcium excretion stayed below this level in the calcium group and the increase was not significantly different from that in the placebo group.
Discussion
This study shows that independent of intervention, cell proliferation (measured predominantly by PCNA immunohistochemistry) in colonic mucosa of adenoma patients correlates positively with patient age and size of the largest diagnosed adenoma. This association with known risk factors for colorectal (11) +5 (9) 100 (24) 109 (12) +10 (24) 0-6 *Wilcoxon rank sum test on the difference between the changes in both groups. tNo collection of faeces and urine in one participant. neoplasia supports the idea of the measurement of cell proliferation to be an adequate biomarker for increased colon cancer risk. The major intention of the study was to investigate whether or not a longterm calcium supplementation would decrease cell proliferation in the sigmoid mucosa of patients treated by polypectomy. A decrease in cell proliferation was evident in both calcium and placebo groups after nine months of intervention. The power of the study permits the conclusion that a longterm calcium intervention in patients treated by polypectomy is unable to normalise the raised proliferative status in the sigmoid colon of these patients. Both patient recruitment and compliance problems were encountered in this study. Forty 26 Both showed increased cell proliferation in high risk patients not only in mucosa adjacent to a neoplastic lesion but in the entire colon and rectum. A more recent study27 where an in vivo injection of BrdU was carried out in 75 patients with adenocarcinoma, showed no difference in proliferative activity between caecum, transverse colon, descending colon, sigmoid, and rectosigmoidal junction. Comparison of these colonic sites with the rectum showed a significantly lower PI% in the rectal mucosa. The distribution of the label along the crypt was also significantly different. Therefore, it cannot be excluded that the inhibiting effect of calcium on cell proliferation may be different in the rectum from that in the colon.
A postulated mechanism by which calcium may exhibit its protective effect on colonic epithelium is by binding free fatty acids and secondary bile acids in the colonic lumen.28 Analysis of faecal lipids before and after six months of intervention in the same study group essentially showed evidence of increased precipitation of calcium salts of fatty acids but this did not lead to a decrease in the concentration of free fatty acids in this study (Weisgerber et al, submitted data). This finding is in agreement with no effect of calcium on cell proliferation.
Another postulated mechanism by which calcium may act on colonic epithelium is direct stimulation of cell differentiation.29 An insight into this can be obtained from the results on calcium excretion in faeces and urine. Renal calcium excretion in these patients was lower than obligatory renal calcium loss under conditions of calcium balance. Renal saving dominating obligatory renal loss is probably caused by a negative calcium balance at entry into the study despite reasonably high calcium intake; the reason for this being a comparatively low calcium absorption. During intervention, almost the entire amount of supplemented calcium was excreted via faeces, again implying a low calcium absorption capacity in this study group.
As shown by the positive correlation between the soluble calcium concentration in faeces and mucosal PI%, it may be necessary for calcium to enter the colonocyte to exhibit its inhibiting effect on crypt cell proliferation. In patients with limited calcium absorption and low calcium uptake into the intestinal cell, high calcium supplementation would not decrease cell proliferation because passive transport through the colonic epithelium is paracellular. Decreasing calcium absorption with increasing age is a well recognised phenomenon and may be one reason why elderly persons exhibit a higher proliferative activity in the intestinal mucosa. Supplementation of 2 g/day calcium in young volunteers (mean age 27 years) does cause urinary calcium to increase significantly from 134 mg to 172 mg on average, indicating increased net calcium absorption.30
As calcium absorption in the colon is dependent on 1,25-dihydroxyvitamin D,3' 32 calcium supplements alone may not be effective in patients with low calcium absorption. Calcium intervention in 79 adenoma patients (mean age 61 years) failed to reduce crypt cell production rate after 12 months compared with placebo.19
The only longterm trial that showed reduction of epithelial proliferation after six months of intervention with 1500 mg/day was conducted in FAP patients (mean age 38 years), whose blood concentrations of vitamin D metabolites were above the normal range, indicating sufficient vitamin D supply. ' 
